skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Bendamustine in the treatment of non-Hodgkin’s lymphomas

Review

(3770) Views  (907) Full article downloads

Authors: Fredrick Hagemeister, George Manoukian

Published Date December 2009 Volume 2009:2 Pages 269 - 279
DOI: http://dx.doi.org/10.2147/OTT.S4873

Fredrick Hagemeister1, George Manoukian2

1Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center Houston, TX, USA; 2Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX, USA

Purpose: To review available data using bendamustine alone and in combination with other chemotherapeutic agents in treatment of patients with non-Hodgkin’s lymphomas.

Methods: Internet database searches and literature review.

Results: Bendamustine was approved in March 2008 by the United States Food and Drug Administration for the treatment of patients with chronic lymphocytic leukemia. Many trials have been performed over the last decade using bendamustine not only as monotherapy, but also in combination with other agents including rituximab, vincristine, mitoxantrone, fludarabine, and other agents as therapy for patients with relapsed non-Hodgkin’s lymphomas, and recently was approved for use in therapy of patients with relapsed indolent lymphomas considered refractory to rituximab therapy. As monotherapy, bendamustine induces good responses with only minor side effects. In combination with other agents, efficacy improves, especially when given in combination with rituximab. The drug has also been studied in combination with rituximab as initial therapy for indolent lymphomas, and has excellent activity with less toxicity than R-CHOP (rituximab – cyclophosphamide, hydroxydaunorubicin [Adriamycin], Oncovin [vincristine], and prednisone/prednisolone).

Conclusion: Overall, bendamustine has demonstrated promising results as therapy for non-Hodgkin’s lymphomas and should be included in the armamentarium of agents used to treat relapsed indolent non-Hodgkin’s lymphomas and may prove valuable as initial therapy for these diseases. Further studies are being conducted to demonstrate the efficacy of this drug in combination with other agents.

Keywords: bendamustine, non-Hodgkin’s lymphomas, relapsed lymphoma








Readers of this article also read:

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
Topotecan in the treatment of relapsed small cell lung cancer
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Multiple roles and therapeutic implications of Akt signaling in cancer
Expanded use of rituximab in the management of non-Hodgkin lymphoma
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
The pathophysiology of bronchiectasis
Health literacy and health seeking behavior among older men in a middle-income nation
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography